Stockscreener 앱 받기
1.25
3.85%
-0.05
시간 외 거래:
1.25
전일 마감가:
$1.30
열려 있는:
$1.29
하루 거래량:
10,526
Relative Volume:
0.77
시가총액:
$6.03M
수익:
순이익/손실:
$-7.04M
주가수익비율:
-0.2855
EPS:
-4.3784
순현금흐름:
$-6.17M
1주 성능:
-7.41%
1개월 성능:
-35.57%
6개월 성능:
+16.82%
1년 성능:
-47.92%
1일 변동 폭
$1.25
$1.39
1주일 범위
$1.25
$1.39
52주 변동 폭
$0.84
$2.68
Alzamend Neuro Inc Stock (ALZN) Company Profile
명칭
Alzamend Neuro Inc
전화
844-722-6333
주소
480 PEACHTREE ROAD NE, SECOND FLOOR, ATLANTA
Compare ALZN vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALZN
Alzamend Neuro Inc
|
1.25 | 6.03M | 0 | -7.04M | -6.17M | -4.3784 |
VRTX
Vertex Pharmaceuticals Inc
|
524.52 | 132.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
245.81 | 98.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
805.67 | 82.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
890.05 | 55.97B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
386.46 | 43.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-10-01 | 개시 | Ascendiant Capital Markets | Buy |
Alzamend Neuro Inc 주식(ALZN)의 최신 뉴스
No shares sold: Alzamend Neuro (ALZN) requests withdrawal of a resale registration. - Stock Titan
Alzamend Neuro (ALZN) Upgraded to Buy: What Does It Mean for the Stock? - Zacks Investment Research
Form 8K Alzamend Neuro Inc For: 29 September By Investing.com - Investing.com South Africa
Alzamend Neuro Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Alzamend Neuro Flags Substantial Going-Concern Doubt After Q1 Loss Widens - minichart.com.sg
Alzamend Neuro, Inc. Q1 2027: Net loss $3.03M, EPS $(0.68) — 10-Q Summary - TradingView
Alzamend Neuro (ALZN) raises cash but says conditions raise doubt it can keep operating - Stock Titan
ALZN Q1'26 Earnings: revenue estimate is 0 USD - TradingView
Alzamend Neuro Inc expected to post a loss of 56 cents a shareEarnings Preview - TradingView
Profusa Regains Nasdaq Compliance for Publicly Held Shares Requirement - Minichart
Alzamend Neuro (NASDAQ: ALZN) plans $25M preferred stock conversion vote - Stock Titan
Anixa Biosciences Inc. (ANIX) Peer Comparison – Compare with Others - Value Research
Alzamend (ALZN) Results Versus Estimates: EPS Clears the Reported Estimate for the Current Session; Market Response: Shares Fall 4.29% in the Available RecordRevenue Guidance Range - vinanet.vn
IPO Databook: Alzamend Neuro (ALZN US)Aug 2026 - Smartkarma
Alzamend Neuro (ALZN) takes first step toward IPO with SEC filing - Stock Titan
Alzamend Neuro (ALZN) files amended insider trading report - Stock Titan
Alzamend’s lithium treatment data accepted for neuroscience meeting - Investing.com
Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC - PR Newswire
Alzamend Neuro's AL001 fMRI abstract accepted for Neuroscience 2026 - scanx.trade
Alzamend (ALZN) Results Check: Reported EPS Tops Expectations for the Current Session; Market Reaction: Shares Move Higher 3.62% in the Current UpdateLong-Term Guidance - vinanet.vn
Palo Alto To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday - benzinga.com
Alzamend (ALZN) Results at a Glance: Profit Per Share Clears Its Benchmark on the Day; Post-Earnings Trading - vinanet.vn
Alzamend to present lithium imaging data at Barcelona workshop - Investing.com South Africa
Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain - Investing News Network
Alzamend to present lithium imaging data at Barcelona workshop By Investing.com - Investing.com Nigeria
Alzamend to present lithium imaging data at Barcelona workshop - Investing.com
Alzamend to present lithium imaging data at Barcelona workshop By Investing.com - Investing.com Canada
Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain - PR Newswire
Alzamend's first-of-its-kind lithium brain imaging data heads to Barcelona - Stock Titan
Alzamend to present lithium imaging data at Barcelona workshop By Investing.com - Investing.com India
Alzamend Neuro (ALZN) Advances 2.1% as Shares Hold Above $1.39 SupportDiagonal Spread Trade - vinanet.vn
Alzamend Neuro (ALZN) Advances 2.1% as Shares Hold Above $1.39 SupportRTH Profile - dars.gov.et
ALZN Q2 2026 Earnings: Narrower-Than-Expected Loss as Clinical Pipeline Remains CentralEarnings Preview - vinanet.vn
Alzamend Neuro (ALZN) Drops 3.5% to $1.38 as Shares Approach Key SupportBreak of Structure - dars.gov.et
Alzamend Neuro (ALZN) Drops 3.5% to $1.38 as Shares Approach Key SupportResistance Breakout Stocks - vinanet.vn
Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending - marketscreener.com
Alzamend Neuro secures $7.5M in initial funding tranche - Investing.com
Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending - PR Newswire
Alzamend Neuro Secures $25 Million Preferred Stock Financing - TipRanks
Alzamend Neuro Secures Up to $25 Million Series D Preferred Financing; $7.5 Million Funded - TradingView
ALZN Q2 2026 Earnings: Narrower-Than-Expected Loss of -$0.47 Highlights Cost DisciplineEstimate Revision Count - vinanet.vn
Alzamend Neuro’s New Lithium Study Puts AL001 in the Bipolar Disorder Spotlight - TipRanks
ALZN|Alzamend Neuro Inc|Price:1.560|Chg%:-0.070 - TradingKey
Alzamend Neuro Inc reports results for the quarter ended April 30Earnings Summary - TradingView
TradingKey - TradingKey
Alzamend Neuro Inc (ALZN) Cash Flow - TradingKey
Alzamend Neuro Inc (ALZN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Alzamend Neuro, Inc. Revenue Breakdown – NASDAQ:ALZN - TradingView
Alzamend Neuro Inc (ALZN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ALZN Q2 2026 Earnings: EPS Beat Surprises Market as Stock RalliesQuarterly Profit Report - vinanet.vn
Alzamend Neuro Inc (ALZN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Alzamend Neuro Inc 주식 (ALZN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| AULT MILTON C III | Director |
Apr 14 '26 |
Buy |
1.00 |
108,388 |
108,897 |
116,648 |
| AULT MILTON C III | Director |
Dec 23 '25 |
Sale |
2.07 |
1,851 |
3,825 |
0 |
| Horne William B. | Director |
Dec 19 '25 |
Sale |
2.12 |
3,333 |
7,059 |
0 |
| McGrath Lynne Fahey | Director |
Oct 23 '25 |
Sale |
2.29 |
30 |
69 |
25 |
| AULT MILTON C III | Director |
Oct 09 '25 |
Sale |
2.32 |
20,397 |
47,390 |
8,260 |
| AULT MILTON C III | Director |
Oct 08 '25 |
Sale |
2.44 |
101,394 |
247,158 |
28,657 |
| AULT MILTON C III | Director |
Oct 07 '25 |
Sale |
2.49 |
57,379 |
142,954 |
68,848 |
| AULT MILTON C III | Director |
Oct 06 '25 |
Sale |
2.45 |
82,033 |
201,268 |
26,227 |
| AULT MILTON C III | Director |
Oct 03 '25 |
Sale |
2.44 |
65,903 |
160,889 |
8,260 |
| AULT MILTON C III | Director |
Oct 02 '25 |
Sale |
2.39 |
20,686 |
49,522 |
74,163 |
4.38%
1.00%
자본화:
|
볼륨(24시간):